Test repositioning for functional assessment of neurological outcome after experimental stroke in mice

Macarena Hernández-Jiménez1,2, Carolina Peña-Martínez1,2, María Del Carmen Godino1,2

  • 1Unidad de Investigación Neurovascular, Departamento de Farmacología, Facultad de Medicina, Universidad Complutense, Madrid, Spain.

Plos One
|May 5, 2017
PubMed

Insights

This study repurposed behavioral tests for early stroke detection in mice. These methods help assess neurological deficits and identify affected brain areas, aiding new drug development.

Area of Science:

  • Neuroscience
  • Cerebrovascular Research
  • Animal Models

Background:

  • Stroke lacks effective treatments beyond fibrinolysis.
  • Evaluating neurological deficits in animal models is challenging.
  • New therapeutic strategies require improved preclinical assessment.

Purpose of the Study:

  • To evaluate non-traditional behavioral tests for neurological assessment in experimental stroke models.
  • To determine the sensitivity of these tests in different stroke models and brain areas.
  • To enhance the preclinical evaluation of neuroprotective drugs.

Main Methods:

  • 225 male mice underwent permanent middle cerebral artery occlusion (pMCAO) or anterior cerebral artery occlusion (pACAO).
  • Neurological deficits were assessed using modified neuroseverity score, footprint test, forced swim test, and elevated plus maze.
  • Behavioral tests were analyzed for their ability to detect deficits in distinct stroke models.

Main Results:

  • Modified neuroseverity score detected early impairment in both pMCAO and pACAO models.
  • Footprint test and elevated plus maze identified short-term deficits in pMCAO but not pACAO.
  • Forced swim test revealed depression-like behavior specifically after left-hemisphere ischemia.

Conclusions:

  • Repositioned neurobehavioral tests offer rapid detection of early ischemic deficits.
  • These tests can discriminate the affected arterial territory and hemisphere.
  • Findings can refine experimental designs for neuroprotective drug development, bridging the research-clinical gap.

Related Concept Videos